Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.J&J’s schizophrenia drug granted EU approval
Connelly is a partner in the Foley & Lardner LLP law firm, where he has served as founding chairman of its Health Law Practice. He was a director
Connelly is a partner in the Foley & Lardner LLP law firm, where he has served as founding chairman of its Health Law Practice. He was a director
Under the terms of the agreement, California-based Dynavax receives a non-exclusive license under Coley’s immunostimulatory oligonucleotide patent estate for the commercialization of Hepsilav. In addition to the initial
The trial involved the selection of the optimal dose of HD-02, the company’s novel drug candidate for the treatment of Huntington’s disease. The dose escalation study evaluated HD-02
The company’s clinical trial results showed that the drug candidate CRx-150 did not significantly decrease inflammation. Alexis Borisy, president and CEO of CombinatoRx, said the level of activity
The company will file the application in the third quarter of 2007 for the drug, which is for the treatment of chronic lymphocytic leukemia (CLL). “Treanda offers a
Spheramine is being developed by Titan in collaboration with Bayer Schering Pharma. Results from the study are expected to be available in the third quarter of 2008. According
The trial was designed to evaluate the safety and efficacy of ispinesib in the second- or third-line treatment of patients with locally advanced or metastatic breast cancer whose
The patients enrolled in this study were using metformin with or without thiazolidinediones. The results showed sustained reductions in blood glucose control parameters, including haemoglobinA1C (HbA1c), for six
The scientists from Oxford University, in collaboration with the US National Institutes of Health, said that the cells are expected to serve as an improved model for human
The interim blinded data covers 122 patients who have received either BiovaxID or control vaccine. The trial showed that approximately 40% of the evaluable patients in the study